Results 11 to 20 of about 187,458 (237)

Targeting Bruton’s Tyrosine Kinase in Inflammatory and Autoimmune Pathologies

Frontiers in Cell and Developmental Biology, 2021
Bruton’s tyrosine kinase (BTK) was discovered due to its importance in B cell development, and it has a critical role in signal transduction downstream of the B cell receptor (BCR).
Stefan F. H. Neys, Rudi W. Hendriks, Odilia B. J. Corneth   +2 more
doaj   +2 more sources

Bruton’s Tyrosine Kinase: An Emerging Key Player in Innate Immunity

Frontiers in Immunology, 2017
Bruton’s tyrosine kinase (BTK) was initially discovered as a critical mediator of B cell receptor signaling in the development and functioning of adaptive immunity.
Alexander N. R. Weber, Zsofia Bittner, Xiao Liu, Truong-Minh Dang, Markus Philipp Radsak, Cornelia Brunner   +5 more
doaj   +2 more sources

Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors.

New England Journal of Medicine, 2022
BACKGROUND Covalent (irreversible) Bruton's tyrosine kinase (BTK) inhibitors have transformed the treatment of multiple B-cell cancers, especially chronic lymphocytic leukemia (CLL).
E. Wang, Xiaoli Mi, Meghan C. Thompson, S. Montoya, R. Notti, Jumana Afaghani, B. Durham, A. Penson, Matthew T. Witkowski, Sydney X Lu, J. Bourcier, Simon J. Hogg, C. Erickson, Daniel Cui, Hana Cho, Michael Singer, T. Totiger, S. Chaudhry, M. Geyer, Alvaro J Alencar, A. Linley, M. Palomba, Catherine C Coombs, Jae H. Park, A. Zelenetz, L. Roeker, M. Rosendahl, D. E. Tsai, K. Ebata, B. Brandhuber, D. Hyman, I. Aifantis, A. Mato, Justin Taylor, O. Abdel-Wahab   +34 more
semanticscholar   +1 more source

Disrupting enzyme fluidity

eLife, 2021
A combination of X-ray crystallography, NMR, and mass spectrometry has revealed how diverse small-molecule inhibitors bind Bruton’s tyrosine kinase and alter the conformation of this enzyme.
Ganesh Srinivasan Anand
doaj   +1 more source

Reining in BTK: Interdomain Interactions and Their Importance in the Regulatory Control of BTK

Frontiers in Cell and Developmental Biology, 2021
Since Dr. Ogden Bruton’s 1952 paper describing the first human primary immunodeficiency disease, the peripheral membrane binding signaling protein, aptly named Bruton’s tyrosine kinase (BTK), has been the target of intense study. Dr. Bruton’s description
Lauren E. Kueffer, Raji E. Joseph, Amy H. Andreotti   +2 more
doaj   +1 more source

The role of Bruton's tyrosine kinase in the immune system and disease

Immunology, 2021
Bruton's tyrosine kinase (BTK) is a TEC kinase with a multifaceted role in B‐cell biology and function, highlighted by its position as a critical component of the B‐cell receptor signalling pathway.
Charlotte McDonald, Charalambos Xanthopoulos, E. Kostareli   +2 more
semanticscholar   +1 more source

Bruton’s Tyrosine Kinase and Its Isoforms in Cancer

Frontiers in Cell and Developmental Biology, 2021
Bruton’s tyrosine kinase (BTK) is a soluble tyrosine kinase with central roles in the development, maturation, and signaling of B cells. BTK has been found to regulate cell proliferation, survival, and migration in various B-cell malignancies.
Xianhui Wang, Leila Kokabee, Mostafa Kokabee, Douglas S. Conklin   +3 more
doaj   +1 more source

Bruton's tyrosine kinase inhibition—An emerging therapeutic strategy in immune‐mediated dermatological conditions

Allergy. European Journal of Allergy and Clinical Immunology, 2022
Bruton's tyrosine kinase (BTK), a member of the Tec kinase family, is critically involved in a range of immunological pathways. The clinical application of BTK inhibitors for B‐cell malignancies has proven successful, and there is strong rationale for ...
P. Mendes‐Bastos, A. Brasileiro, P. Kolkhir, Stefan Frischbutter, J. Scheffel, S. Moñino-Romero, M. Maurer   +6 more
semanticscholar   +1 more source

Phase I/II study of tirabrutinib, a second-generation Bruton’s tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma

Neuro-Oncology, 2020
Background The safety, tolerability, efficacy, and pharmacokinetics of tirabrutinib, a second-generation, highly selective oral Bruton’s tyrosine kinase inhibitor, were evaluated for relapsed/refractory primary central nervous system lymphoma (PCNSL ...
Y. Narita, M. Nagane, K. Mishima, Y. Terui, Y. Arakawa, Hajime Yonezawa, K. Asai, N. Fukuhara, K. Sugiyama, N. Shinojima, Junsaku Kitagawa, Arata Aoi, R. Nishikawa   +12 more
semanticscholar   +1 more source

Inhibitors targeting Bruton’s tyrosine kinase in cancers: drug development advances

Leukemia, 2020
Bruton’s tyrosine kinase (BTK) inhibitor is a promising novel agent that has potential efficiency in B-cell malignancies. It took approximately 20 years from target discovery to new drug approval.
T. Wen, Jin-song Wang, Yuankai Shi, H. Qian, Peng Liu   +4 more
semanticscholar   +1 more source